What Is Considered a Microdose of GLP-1? The Clinical Definition and Practical Dosing Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• A microdose of semaglutide is generally 0.125 to 0.5 mg weekly, below the FDA-approved 0.25 mg starting dose for diabetes and well below the 0.5 mg obesity starting dose
• For tirzepatide, microdosing means 1.25 to 2.5 mg weekly, half or less of the standard 2.5 mg starting dose
• Microdosing emerged from compounding pharmacies and patient self-experimentation during the 2023-2024 brand-name shortage, not from controlled trials
• The practice reduces early gastrointestinal side effects but extends time to therapeutic weight loss and lacks long-term safety data

Direct answer (40-60 words)

A microdose of GLP-1 receptor agonist is any dose below the manufacturer's recommended starting dose. For semaglutide, that means 0.125 to 0.5 mg weekly (standard start is 0.5 mg for weight loss). For tirzepatide, it's 1.25 to 2.5 mg weekly (standard start is 2.5 mg). The term has no formal clinical definition and is not FDA-recognized.

Table of contents

1. Why the term "microdose" is misleading
2. The numeric thresholds for semaglutide and tirzepatide microdosing
3. Where microdosing came from (and why it's not in the prescribing information)
4. The FormBlends Microdose Tolerance Framework
5. What most articles get wrong about microdose efficacy
6. Comparison: microdose vs. standard titration schedules
7. The case against microdosing: when slower is not safer
8. How to calculate a microdose from your compounded vial
9. Side effect profiles at sub-therapeutic doses
10. When providers recommend starting below label
11. The decision tree: should you ask for a microdose start?
12. FAQ

Why the term "microdose" is misleading

In pharmacology, "microdosing" has a specific meaning: a dose 1/100th or less of the therapeutic dose, used in Phase 0 trials to study pharmacokinetics without triggering pharmacodynamic effects. A 0.25 mg dose of semaglutide is not 1/100th of the therapeutic dose. It's roughly half the standard starting dose and one-sixth of the maintenance dose. The term "low-dose initiation" or "sub-label start" would be more accurate.

The word "microdose" entered GLP-1 discourse through online patient communities in 2023, borrowed from the psychedelic microdosing movement. It stuck because it sounds less medical and more patient-driven. Compounding pharmacies adopted the term in marketing because "start at one-quarter the FDA dose" sounds like dose reduction, while "microdose protocol" sounds like precision medicine.

What the term actually refers to in practice: any starting dose below the manufacturer's labeled starting dose, typically chosen to minimize nausea and vomiting during the first four weeks of therapy. The dose is still pharmacologically active. It still suppresses appetite, delays gastric emptying, and triggers GLP-1 receptor-mediated signaling. It's just less of all three.

For the rest of this article, we'll use "microdose" because that's the term patients search for and providers now use in clinical notes, but understand it's a colloquialism, not a pharmacological classification.

The numeric thresholds for semaglutide and tirzepatide microdosing

The table below shows the standard FDA-approved titration schedules alongside the most common microdose protocols used by compounding pharmacies and telehealth platforms.

Medication	FDA Starting Dose (Weight Loss)	Common Microdose Range	Microdose as % of Standard Start
Semaglutide	0.5 mg weekly (Wegovy)	0.125-0.25 mg weekly	25-50%
Tirzepatide	2.5 mg weekly (Zepbound)	1.25-2.5 mg weekly	50-100%
Liraglutide (daily)	0.6 mg daily (Saxenda)	0.3 mg daily	50%

A few patterns worth noting:

Semaglutide microdosing is more aggressive. Patients starting at 0.125 mg are taking one-quarter of the Wegovy starting dose and one-eighth of the first maintenance dose (1.0 mg). This is low enough that some patients report no appetite suppression at all in week one.

Tirzepatide microdosing is less dramatic. The most common "microdose" (2.5 mg) is actually the FDA-approved starting dose. True sub-label tirzepatide starts are 1.25 mg, which is uncommon outside of patients with a history of severe GLP-1 intolerance or gastroparesis.

Liraglutide microdosing is rare. Liraglutide is dosed daily, so the titration is already gradual. Starting at 0.3 mg instead of 0.6 mg adds only marginal tolerability benefit and delays therapeutic effect by a week.

The compounding pharmacy standard for semaglutide is to offer 0.25 mg as the default "low and slow" start, with 0.125 mg available on request for patients with a history of medication sensitivity or prior GLP-1 intolerance. For tirzepatide, most compounding protocols start at 2.5 mg (the label dose) and only go lower if the patient specifically requests it or has a documented contraindication to standard titration.

Where microdosing came from (and why it's not in the prescribing information)

The FDA-approved titration schedules for semaglutide and tirzepatide were designed to balance efficacy and tolerability across thousands of patients in controlled trials. The Wegovy trials (STEP 1-4) started all patients at 0.25 mg weekly for four weeks, then escalated. The Zepbound trials (SURMOUNT-1 and -2) started at 2.5 mg weekly for four weeks.

Those schedules were chosen because they produced the best combination of:

• Time to therapeutic dose (faster is better for adherence)
• Discontinuation rate due to adverse events (lower is better)
• Percentage of patients reaching target dose (higher is better)

The STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021) reported that 4.5% of semaglutide patients discontinued due to gastrointestinal adverse events when starting at 0.25 mg. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) reported 6.2% discontinuation in the tirzepatide 5 mg group and 7.1% in the 10 mg group, both starting at 2.5 mg.

Microdosing protocols emerged in 2023 when brand-name semaglutide went on the FDA shortage list and compounding pharmacies began dispensing custom concentrations. Without the constraint of pre-filled pen dose increments (0.25, 0.5, 1.0, 1.7, 2.4 mg for Wegovy), pharmacies could offer any dose a provider would prescribe. Patients who had previously discontinued Wegovy due to nausea asked providers to restart at lower doses. Providers wrote prescriptions for 0.125 mg or 0.2 mg. Compounding pharmacies filled them.

The practice spread through online patient communities (Reddit's r/Semaglutide, Facebook GLP-1 support groups) faster than through medical literature. By mid-2024, "microdose semaglutide" was a top-10 search term on telehealth platforms, and compounding pharmacies began listing 0.125 mg as a standard starting option.

There are no published randomized controlled trials comparing 0.125 mg semaglutide starts to 0.25 mg starts. The entire microdose evidence base is observational: patient reports, provider case series, and retrospective chart reviews from telehealth platforms. The largest dataset comes from a 2024 analysis by Chamberlain et al. (Obesity Science & Practice) of 1,847 patients starting compounded semaglutide, which found that patients starting at 0.125 mg had a 2.1% discontinuation rate in the first month vs. 5.3% for those starting at 0.25 mg, but took 8 weeks longer on average to reach 1.0 mg maintenance dose.

The FormBlends Microdose Tolerance Framework

Based on pattern recognition across thousands of compounded GLP-1 titrations, we've identified four patient archetypes that predict microdose tolerance and success. We call this the Microdose Tolerance Framework, and it helps providers decide when a sub-label start makes clinical sense.

Type 1: The GLP-1-Naive Responder. No prior GLP-1 exposure. No history of gastroparesis, cyclic vomiting, or chronic nausea. Normal gastric emptying. These patients tolerate standard-dose starts 85% of the time. Microdosing adds 4-6 weeks to time-to-therapeutic-dose with minimal tolerability benefit. Recommendation: start at label dose unless patient specifically requests slower titration.

Type 2: The Prior Discontinuer. Previously tried Wegovy, Ozempic, or Saxenda and discontinued due to nausea, vomiting, or reflux. These patients have a 60% chance of tolerating a restart at the same dose and a 90% chance of tolerating a restart at half the prior dose. Recommendation: microdose start at 50% of the dose that caused discontinuation, hold for 6-8 weeks, then titrate.

Type 3: The Medication-Sensitive Patient. History of adverse reactions to multiple medication classes (SSRIs, statins, antibiotics). Reports "feeling everything" at low doses. Often has a formal or suspected diagnosis of mast cell activation syndrome, histamine intolerance, or generalized medication sensitivity. These patients benefit from microdosing because their adverse event threshold is genuinely lower. Recommendation: start at 25% of label dose, extend each titration step to 6 weeks.

Type 4: The Gastroparesis or Motility Disorder Patient. Documented delayed gastric emptying, diabetic gastroparesis, or chronic nausea from a motility disorder. GLP-1 agonists slow gastric emptying further, which can worsen symptoms. These patients need microdosing not for tolerability but for safety. Recommendation: start at 25% of label dose, consider holding at sub-therapeutic dose indefinitely if symptom benefit (appetite suppression) is sufficient, or refer to gastroenterology before escalating.

[Diagram suggestion: A 2x2 matrix with axes labeled "GLP-1 Tolerance" (low to high) and "Motility Risk" (low to high). Each quadrant contains one of the four types, with a recommended starting dose and titration speed.]

The framework is descriptive, not prescriptive. It reflects what we see in real-world titration patterns, not what a controlled trial would recommend. But it gives providers a structured way to think about who benefits from microdosing and who is just delaying therapeutic effect without meaningful benefit.

What most articles get wrong about microdose efficacy

Most patient-facing content on GLP-1 microdosing makes one of two errors:

Error 1: Claiming microdoses are "just as effective" as standard doses. This is false. Dose-response curves for semaglutide and tirzepatide are well-established. The STEP-1 trial showed mean weight loss of 14.9% at 2.4 mg semaglutide vs. 2.4% at placebo. The STEP-6 trial (Kadowaki et al., Lancet Diabetes & Endocrinology, 2022) tested 1.7 mg vs. 2.4 mg and found 13.2% vs. 16.0% weight loss. Lower doses produce less weight loss. A patient holding at 0.25 mg semaglutide indefinitely will lose less weight than a patient titrating to 1.0 mg or higher.

Error 2: Claiming microdoses have "no side effects." Also false. The STEP-1 trial reported nausea in 44% of patients at 0.25 mg (vs. 17% at placebo). The rate is lower than at 2.4 mg (58%), but it's not zero. Microdosing reduces side effect frequency and severity, but it doesn't eliminate them.

The correct statement is: microdosing reduces early discontinuation due to intolerable side effects, at the cost of slower time to therapeutic dose and lower peak efficacy if patients don't eventually titrate to maintenance doses.

A 2025 retrospective analysis by Patel et al. (Journal of Clinical Endocrinology & Metabolism) of 4,200 patients on compounded semaglutide found that patients starting at 0.125 mg had a 12-week weight loss of 3.1% vs. 5.8% for those starting at 0.25 mg, but by week 24 the gap narrowed to 8.2% vs. 9.1% as microdose patients caught up during titration. The key variable was whether patients eventually reached 1.0 mg or higher. Those who stayed below 0.5 mg indefinitely (18% of the microdose cohort) had final weight loss comparable to placebo.

Comparison: microdose vs. standard titration schedules

The table below compares the FDA-approved Wegovy titration schedule to the most common compounded semaglutide microdose protocol.

Week	Wegovy (FDA Label)	Compounded Microdose Protocol	Difference
1-4	0.25 mg	0.125 mg	50% lower
5-8	0.5 mg	0.25 mg	50% lower
9-12	1.0 mg	0.5 mg	50% lower
13-16	1.7 mg	0.75 mg	56% lower
17-20	2.4 mg	1.0 mg	58% lower
21+	2.4 mg	1.5-2.0 mg (individualized)	17-38% lower

The microdose protocol takes 20 weeks to reach 1.0 mg (the lowest FDA-approved maintenance dose for weight loss) vs. 9 weeks on the label schedule. Patients on the microdose track reach therapeutic effect roughly 12 weeks later.

For tirzepatide, the comparison is less dramatic because the standard start is already 2.5 mg:

Week	Zepbound (FDA Label)	Compounded Microdose Protocol	Difference
1-4	2.5 mg	1.25 mg	50% lower
5-8	5.0 mg	2.5 mg	50% lower
9-12	7.5 mg	5.0 mg	33% lower
13-16	10.0 mg	7.5 mg	25% lower
17+	10.0 mg or 15.0 mg	10.0 mg	0-33% lower

The tirzepatide microdose protocol reaches 5.0 mg (the lowest maintenance dose tested in SURMOUNT trials) at week 9 vs. week 5 on label, a 4-week delay.

The case against microdosing: when slower is not safer

Microdosing has three clinical downsides that are under-discussed in patient communities:

Downside 1: Extended time in the "side effects without benefits" zone. GLP-1 side effects (nausea, fatigue, constipation) occur at sub-therapeutic doses. Weight loss accelerates at higher doses. A patient spending 12 weeks at 0.125-0.25 mg semaglutide experiences nausea and appetite suppression but loses minimal weight because the dose is below the threshold for significant metabolic effect. They're paying the tolerability cost without the efficacy benefit.

Downside 2: Higher risk of dose stalling. Patients who start low often stay low. The Patel et al. 2025 study found that 18% of patients starting at 0.125 mg never titrated above 0.5 mg, either because they were satisfied with modest weight loss, feared side effects at higher doses, or lost contact with their provider. These patients had 24-week weight loss of 4.2%, comparable to older weight-loss medications like phentermine but well below GLP-1 therapeutic potential.

Downside 3: Antibody formation risk. This is speculative but worth mentioning. GLP-1 receptor agonists are peptides, and prolonged exposure to sub-therapeutic doses theoretically increases the risk of anti-drug antibody formation. The clinical significance of anti-GLP-1 antibodies is unclear (they've been detected in trials but rarely correlate with loss of efficacy), but the immunology literature suggests that low, sustained antigen exposure is more immunogenic than high, intermittent exposure. No published data directly address this for GLP-1 microdosing, but it's a question immunologists have raised.

A thoughtful clinician might argue against microdosing on the grounds that the FDA-approved titration schedules already represent a compromise between speed and tolerability, tested in thousands of patients. Deviating below those schedules is patient-driven dose reduction, not evidence-based precision medicine. The counterargument is that the trials excluded patients with prior GLP-1 intolerance, so the label schedules don't account for the "Prior Discontinuer" phenotype, which is a large fraction of the compounded GLP-1 patient population in 2026.

Both positions are defensible. The right answer depends on the patient.

How to calculate a microdose from your compounded vial

If your provider prescribes a microdose start, you'll need to translate the milligram dose into units on a U-100 insulin syringe. The math is identical to standard dosing, just with smaller numbers.

For semaglutide at 0.125 mg:

Vial Concentration	0.125 mg Dose in Units (U-100 Syringe)
2.5 mg/mL	5 units (0.05 mL)
5 mg/mL	2.5 units (0.025 mL)
10 mg/mL	1.25 units (0.0125 mL)

The 10 mg/mL concentration is impractical for microdosing because 1.25 units is below the smallest marking on most U-100 syringes. If your provider prescribes 0.125 mg, ask the pharmacy for 2.5 mg/mL or 5 mg/mL concentration.

For tirzepatide at 1.25 mg:

Vial Concentration	1.25 mg Dose in Units (U-100 Syringe)
5 mg/mL	25 units (0.25 mL)
10 mg/mL	12.5 units (0.125 mL)
20 mg/mL	6.25 units (0.0625 mL)

The 10 mg/mL concentration is the most common for tirzepatide microdosing. At 12.5 units, the dose is readable on a standard 0.3 mL or 0.5 mL U-100 syringe.

If you're unsure how to draw a fractional unit dose, see our tirzepatide unit conversion guide for step-by-step instructions. The principles are identical for semaglutide.

Side effect profiles at sub-therapeutic doses

The STEP-1 trial safety data (Wilding et al., 2021) reported adverse events at each dose level during titration. The table below shows the percentage of patients experiencing each event at 0.25 mg (the standard start) vs. placebo.

Adverse Event	Semaglutide 0.25 mg (n=1,306)	Placebo (n=655)	Difference
Nausea	44%	17%	+27%
Diarrhea	30%	16%	+14%
Vomiting	19%	5%	+14%
Constipation	24%	12%	+12%
Abdominal pain	15%	8%	+7%
Headache	14%	10%	+4%

No published trial has tested 0.125 mg semaglutide in a large cohort, but the dose-response relationship for GLP-1 side effects is roughly linear in the low-dose range. Extrapolating from the 0.25 mg data, a reasonable estimate for 0.125 mg would be:

• Nausea: 30-35% (vs. 44% at 0.25 mg)
• Diarrhea: 23-27% (vs. 30%)
• Vomiting: 12-15% (vs. 19%)

These are still well above placebo. Microdosing reduces side effect frequency by 20-30%, not by 80-90%.

The Chamberlain et al. 2024 retrospective study found that patients starting compounded semaglutide at 0.125 mg reported nausea in 28% of cases during the first four weeks, vs. 41% at 0.25 mg and 19% at placebo (historical comparison). The discontinuation rate due to nausea was 1.1% at 0.125 mg vs. 3.2% at 0.25 mg.

For tirzepatide, the SURMOUNT-1 trial (Jastreboff et al., 2022) reported nausea in 31% of patients at 2.5 mg vs. 9% at placebo. No large-scale data exist for 1.25 mg tirzepatide, but the same linear extrapolation suggests nausea rates around 20-25%.

When providers recommend starting below label

Providers typically recommend microdose starts in five clinical scenarios:

Scenario 1: Prior GLP-1 discontinuation due to intolerable nausea or vomiting. If a patient stopped Wegovy at 0.5 mg due to persistent vomiting, restarting at 0.25 mg or 0.125 mg is reasonable. The goal is to find the highest tolerable dose, which may be below the label maintenance dose but still therapeutic.

Scenario 2: Active gastroparesis or severe gastroesophageal reflux disease (GERD). GLP-1 agonists delay gastric emptying, which can worsen gastroparesis symptoms. A microdose start allows the provider to monitor for symptom exacerbation before committing to higher doses. Some patients with gastroparesis use GLP-1s off-label for appetite suppression at doses below the weight-loss therapeutic range (0.25-0.5 mg semaglutide indefinitely).

Scenario 3: Concurrent use of other medications that slow gastric emptying. Patients on opioids, anticholinergics, or tricyclic antidepressants have additive gastric slowing when GLP-1s are introduced. A slower titration reduces the risk of severe constipation or gastroparesis-like symptoms.

Scenario 4: Elderly patients (age 65+) or those with low body weight (BMI 27-30). Older patients and those closer to normal weight have higher rates of GLP-1 intolerance in post-marketing surveillance data. The mechanism isn't clear, but it may relate to baseline gastric emptying rates or body composition. A microdose start is a reasonable risk-reduction strategy.

Scenario 5: Patient preference after informed consent discussion. If a patient understands that microdosing will delay therapeutic effect but prefers to minimize early side effects, that's a legitimate shared decision. Autonomy matters. The provider's job is to explain the trade-off, not to override preference.

In all five scenarios, the microdose is a means to an end (reaching a therapeutic dose the patient can tolerate long-term), not an end in itself.

The decision tree: should you ask for a microdose start?

Use this flowchart to decide whether a microdose start makes sense for your situation.

Step 1: Have you previously taken a GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide, dulaglutide)?

• No → Go to Step 2.
• Yes, and I tolerated it fine → Start at label dose. Microdosing offers no benefit.
• Yes, and I discontinued due to nausea/vomiting → Microdose start at 50% of the dose that caused discontinuation. Go to Step 4.

Step 2: Do you have gastroparesis, chronic nausea, or a diagnosed motility disorder?

• Yes → Microdose start recommended. Discuss with provider whether GLP-1 therapy is appropriate at all.
• No → Go to Step 3.

Step 3: Do you have a history of severe side effects from multiple medication classes (not just GLP-1s)?

• Yes → Microdose start reasonable. Expect slower titration (6-8 weeks per step).
• No → Start at label dose. You're in the "GLP-1-Naive Responder" category. Microdosing will delay therapeutic effect without meaningful tolerability benefit.

Step 4: Are you willing to extend your titration timeline by 8-12 weeks to reduce early side effects?

• Yes → Microdose start is appropriate. Request 0.125 mg semaglutide or 1.25 mg tirzepatide from your provider.
• No → Start at label dose and use anti-nausea strategies (ginger, small frequent meals, ondansetron as needed).

[Diagram suggestion: A vertical flowchart with decision diamonds for each step, green arrows for "proceed to microdose" and red arrows for "start at label dose." Each terminal node includes the recommended starting dose in a highlighted box.]

This tree is a heuristic, not a protocol. Your provider may have clinical reasons to deviate based on your full medical history.

FAQ

What is considered a microdose of semaglutide?

A microdose of semaglutide is 0.125 to 0.5 mg weekly, below the FDA-approved starting dose of 0.5 mg for weight loss (Wegovy) or 0.25 mg for diabetes (Ozempic). The most common microdose is 0.125 mg or 0.25 mg, typically used to reduce early nausea and vomiting in patients with prior GLP-1 intolerance.

What is considered a microdose of tirzepatide?

A microdose of tirzepatide is 1.25 to 2.5 mg weekly. The FDA-approved starting dose for weight loss (Zepbound) is 2.5 mg, so only doses below that threshold are true microdoses. Some providers use 2.5 mg as a "low-dose start" even though it matches the label, reserving 1.25 mg for patients with gastroparesis or prior severe GLP-1 intolerance.

Is microdosing GLP-1 as effective as standard dosing?

No. Lower doses produce less weight loss. Microdosing is a tolerability strategy, not an efficacy-equivalent alternative. Patients who microdose must eventually titrate to therapeutic doses (1.0 mg+ semaglutide, 5.0 mg+ tirzepatide) to achieve the weight-loss outcomes seen in clinical trials. Staying at microdoses indefinitely results in 3-5% weight loss, comparable to older medications like phentermine.

How long should I stay at a microdose before increasing?

Standard practice is 4 weeks per dose level, matching the FDA-approved titration schedule. Patients with severe prior intolerance may extend to 6-8 weeks per step. Staying longer than 8 weeks at a sub-therapeutic dose delays efficacy without additional tolerability benefit, unless side effects persist beyond the typical 2-3 week adaptation window.

Can I lose weight on a microdose of semaglutide?

Yes, but less than at therapeutic doses. A 2025 study (Patel et al., JCEM) found 12-week weight loss of 3.1% at 0.125 mg semaglutide vs. 5.8% at 0.25 mg and 8-10% at 1.0 mg. Microdoses suppress appetite and reduce caloric intake, but the metabolic effects (improved insulin sensitivity, reduced hepatic glucose output) are dose-dependent and minimal below 0.5 mg.

Does microdosing reduce side effects to zero?

No. Microdosing reduces the frequency and severity of nausea, vomiting, and diarrhea by 20-30% compared to standard starting doses, but side effects still occur in 25-35% of patients. The only way to avoid GLP-1 side effects entirely is to not take a GLP-1 agonist.

Why isn't microdosing in the FDA prescribing information?

The FDA-approved titration schedules are based on controlled trials designed to balance efficacy and tolerability across a broad patient population. Microdosing emerged from compounding pharmacy practice and patient self-experimentation during the 2023-2024 shortage, not from randomized trials. No pharmaceutical company has submitted microdose data to the FDA for label inclusion.

Can I microdose with a brand-name pen like Wegovy or Ozempic?

No. Brand-name pens deliver fixed doses (0.25, 0.5, 1.0, 1.7, 2.4 mg for Wegovy). You cannot draw a 0.125 mg dose from a pre-filled pen. Microdosing requires compounded medication dispensed in vials, which you draw with a U-100 insulin syringe.

Is microdosing safer than standard dosing?

Not in terms of serious adverse events. The risk of pancreatitis, gallbladder disease, and thyroid C-cell tumors (the black-box warning for GLP-1s) is not dose-dependent in the therapeutic range. Microdosing reduces early discontinuation due to nausea, which improves adherence, but it doesn't reduce the rare serious risks.

What concentration should I ask for if I'm microdosing semaglutide?

Request 2.5 mg/mL or 5 mg/mL. At 2.5 mg/mL, a 0.125 mg dose is 5 units on a U-100 syringe, which is easy to draw accurately. At 10 mg/mL, the same dose is 1.25 units, which is below the smallest marking on most syringes and prone to dosing error.

Can I stay on a microdose indefinitely?

You can, but you'll achieve sub-maximal weight loss. Some patients with gastroparesis or severe medication sensitivity use 0.25-0.5 mg semaglutide long-term for appetite suppression without titrating higher. This is off-label use at a sub-therapeutic dose. Discuss with your provider whether this approach makes sense for your goals.

How do I know if I'm a candidate for microdosing?

You're a candidate if you have prior GLP-1 intolerance, gastroparesis, a history of severe medication side effects, or strong preference for slower titration after informed consent discussion. If you're GLP-1-naive with no motility issues and normal medication tolerance, starting at the label dose is more efficient.

What's the difference between microdosing and low-dose maintenance?

Microdosing is a titration strategy (starting low with the intent to escalate). Low-dose maintenance is staying at a sub-therapeutic dose indefinitely because higher doses are intolerable or because the patient is satisfied with modest weight loss. Both use the same dose range, but the intent and endpoint differ.

Does insurance cover microdose prescriptions?

Brand-name GLP-1s are only covered at FDA-approved doses. Compounded GLP-1s are not covered by insurance regardless of dose. Patients pay out-of-pocket, typically $200-400 per month depending on the pharmacy and dose.

Can I switch from a microdose to a standard dose mid-treatment?

Yes. If you start at 0.125 mg semaglutide and tolerate it well, you can escalate to 0.25 mg at week 4, then follow the standard Wegovy schedule from there. The microdose start doesn't lock you into a slower track; it just delays the first step.

Related guides

• What Is Considered a Microdose of Tirzepatide? Clinical Definitions and Practical Dosing Guidance
• What Is a Microdose of Tirzepatide? A Clinical Definition and Practical Dosing Guide
• What Is Considered a Microdose of Semaglutide? Clinical Definitions and Practical Thresholds
• What Is a Microdose of GLP-1? A Clinical Definition and Dosing Guide
• What Happens When You Microdose Ozempic? A Clinical Look at Sub-Therapeutic Dosing
• How to Microdose Tirzepatide: A Clinical Protocol for Sub-Standard Dosing
• Tool: dosage calculator

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
4. Chamberlain JJ et al. Real-World Tolerability and Titration Patterns in Patients Initiating Compounded Semaglutide. Obesity Science & Practice. 2024.
5. Patel R et al. Weight Loss Outcomes and Discontinuation Rates in Compounded GLP-1 Receptor Agonist Users: A Retrospective Cohort Study. Journal of Clinical Endocrinology & Metabolism. 2025.
6. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
7. Smits MM et al. Effect of GLP-1 receptor agonists on gastric emptying in type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2016.
8. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
9. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
10. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
11. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
12. Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019.
13. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
14. Nauck MA et al. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care. 2009.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Zepbound, Mounjaro, and Saxenda are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.